New drug aims to stop kidney disease relapses
NCT ID NCT07499700
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called BAT4406F in people with two rare kidney conditions: Minimal Change Disease and Focal Segmental Glomerulosclerosis. The goal is to see if it can reduce protein in the urine and prevent the disease from coming back. About 192 participants will receive either the drug or a placebo by IV infusion, and researchers will track their progress over several months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BAT4406F injection
- What this could lead to
- If it works, this could offer a new treatment option to control protein leakage and reduce relapses in people with MCD or FSGS.
- What could go wrong
- This is an early-to-mid-stage trial with only 192 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a targeted antibody outdo steroids for a rare kidney disease?
- Immune cells may hold key to predicting kidney disease relapse
- Kidney disease mystery: scientists launch massive data hunt
- New pill aims to plug protein leak in kidney patients
- Scientists hunt for hidden antibodies in Kids' kidney disease